The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Tri...
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
About this item
Full title
Author / Creator
Wiviott, Stephen D. , Raz, Itamar , Bonaca, Marc P , Mosenzon, Ofri , Kato, Eri T , Cahn, Avivit , Silverman, Michael G , Bansilal, Sameer , Bhatt, Deepak L , Leiter, Lawrence A. , McGuire, Darren K. , Wilding, John PH , Gause-Nilsson, Ingrid AM , Langkilde, Anna Maria , Johansson, Peter A. and Sabatine, Marc S.
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT-2) inhibitor that reduces blood glucose in patients with type 2 diabetes mellitus (T2DM) by promoting glycosuria via inhibiting urinary glucose reabsorption. In addition to improving blood glucose control, treatment with dapagliflozin results in glucose-induced osmotic diuresis, weight loss,...
Alternative Titles
Full title
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2052675474
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2052675474
Other Identifiers
ISSN
0002-8703
E-ISSN
1097-6744
DOI
10.1016/j.ahj.2018.01.012
